Val Romberg

Val Romberg is responsible for the development of important new and improved protein-based medicines that save lives by preventing or treating serious medical conditions.  He oversees clinical research and development, pharmacovigilance and medical services, regulatory affairs, product and process development, virology and pathogen safety and project management at four sites.  In this capacity, he works closely with CSL Research and Development in Parkville, Australia.

Mr. Romberg has more than 25 years of experience in the pharmaceutical industry.  Mr. Romberg joined West Pharmaceuticals in 1984 where his background in polymer chemistry was utilized to develop controlled release systems for delivery of pharmaceuticals to the eye and the colon.  In 1995, he was promoted to a joint marketing/technical role to commercialize new products.

In 1998, Mr. Romberg joined Centeon, a predecessor company of CSL Behring, as a project manager in King of Prussia, Pennsylvania.  In this role, he was involved in the development of several products, both recombinant and plasma derived.  In 2003, he assumed the role of Senior Director, Technical Operations in Kankakee, Illinois in manufacturing for Aventis Behring.  In 2004, as a member of the Kankakee management team, he participated in the restructuring of the site, the start up of Building 21, and the initiation of the manufacture of ISCOMATRIX^®. In July 2006, he became Senior Director, Research & Development, in Bern, Switzerland, focusing on the development of immunoglobulins.

Mr. Romberg has a Bachelor’s degree in chemistry from the University of Michigan.